Sosei Heptares to Utilize its Structure-Based Drug Design Expertise in New COVID-19 R&D Program

 Sosei Heptares to Utilize its Structure-Based Drug Design Expertise in New COVID-19 R&D Program

Sosei Heptares to Utilize its Structure- Based Drug Design Expertise in New COVID-19 R&D ProgramSosei Heptares to Utilize its Structure- Based Drug Design Expertise in New COVID-19 R&D Program

Shots:

  • The company will apply its unique structure-based drug design platform and capabilities to the global research efforts to discover drugs targeting COVID-19
  • Sosei Heptares has initiated a new R&D program to identify compounds blocking the activity of SARS-CoV-2 MPro protease (Nsp5), which has been designated as a potential target for drug development
  • The company is looking for a collaboration with other partners to support the program and all the finding will be freely accessible to the global research community looking for the treatments of COVID-19

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: News Scientist

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post